About Tobacco Alternative Gums
Tobacco alternative gums are products such as nicotine gums, which are used by smokers to quit smoking. Nicotine gum is a smoking cessation product, which helps smokers to gradually get off nicotine. Nicotine released from chewing nicotine gum is absorbed into the bloodstream through the lining of the mouth. Nicotine gums help the human body battle the strong urges for nicotine after cutting down on cigarettes. They are available in various dosages and can be consumed according to the level of addiction.
Technavio’s analysts forecast the global tobacco alternative gum market to grow at a CAGR of 7.52% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global tobacco alternative gum market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of tobacco alternative gum.
The market is divided into the following segments based on geography:
• Americas
• APAC
• Europe
• MEA
Technavio's report, Global Tobacco Alternative Gums Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• GlaxoSmithKline
• Johnson & Johnson
• Novartis
• Reynolds American Incorporated
Other prominent vendors
• Alkalon
• Costco
• Revolymer
• Target
• Walgreen
• Wal-Mart
Market driver
• Increase in number of people quitting smoking
• For a full, detailed list, view our report
Market challenge
• Stringent government regulations
• For a full, detailed list, view our report
Market trend
• Introduction of new flavors
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Key market highlights
PART 05: Market landscape
• Market overview
• Global smoking cessation market
• Global tobacco alternative gums market
• Five forces analysis
PART 06: Market segmentation by nicotine content
• Global 2-mg nicotine gum market
• Global 4-mg nicotine gum market
PART 07: Market segmentation by distribution channel
PART 08: Geographical segmentation
• Tobacco alternative gums market in Americas
• Tobacco alternative gums market in Europe
• Tobacco alternative gums market in APAC
• Tobacco alternative gums market in MEA
PART 09: Key leading countries
• US
• Germany
• France
• China
PART 10: Market drivers
PART 11: Impact of drivers
PART 12: Market challenges
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
• Competitive scenario
• GlaxoSmithKline
• Johnson & Johnson
• Novartis
• Reynolds American Incorporated
• Other prominent vendors
PART 16: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Percentage of people smoking in various countries 2015
Exhibit 02: Overview of global tobacco alternative gums market 2016
Exhibit 03: Global smoking cessation market 2016-2021 ($ billions)
Exhibit 04: Global tobacco alternative gums market 2016-2021 ($ billions)
Exhibit 05: Five forces analysis
Exhibit 06: Global tobacco alternative gums market by nicotine content 2016 and 2021
Exhibit 07: Global 2-mg nicotine gum market 2016-2021 ($ billions)
Exhibit 08: Global 4-mg nicotine gum market 2016-2021 ($ billions)
Exhibit 09: Global tobacco alternative gums market by distribution channel 2016
Exhibit 10: Global tobacco alternative gums market by geography 2016 and 2021
Exhibit 11: Tobacco alternative gums market in Americas 2016-2021 ($ billions)
Exhibit 12: Tobacco alternative gums market in Europe 2016-2021 ($ billions)
Exhibit 13: Tobacco alternative gums market in APAC 2016-2021 ($ billions)
Exhibit 14: Tobacco alternative gums market in MEA 2016-2021 ($ billions)
Exhibit 15: Key leading countries
Exhibit 16: Tobacco alternative gums market in US 2016-2021 ($ billions)
Exhibit 17: Tobacco alternative gums market in Germany 2016-2021 ($ billions)
Exhibit 18: Tobacco alternative gums market in France 2016-2021 ($ billions)
Exhibit 19: Tobacco alternative gums market in China 2016-2021 ($ billions)
Exhibit 20: Impact of drivers
Exhibit 21: Impact of drivers and challenges
Exhibit 22: Competitive assessment of major players in global tobacco alternative gums market
Exhibit 23: GlaxoSmithKline: Business segmentation by revenue 2015 ($ billions)
Exhibit 24: GlaxoSmithKline: Operating profit comparison 2014 and 2015 ($ billions)
Exhibit 25: GlaxoSmithKline: EBITDA comparison 2014 and 2015 ($ billions)
Exhibit 26: GlaxoSmithKline in global tobacco alternative gums market
Exhibit 27: Johnson & Johnson manufacturing facilities by geography
Exhibit 28: Johnson & Johnson: Business segmentation by revenue 2015 ($ billions)
Exhibit 29: Johnson & Johnson: Total sales comparison 2014 and 2015 ($ billions)
Exhibit 30: Johnson & Johnson: EBITDA comparison 2014 and 2015 ($ billions)
Exhibit 31: Johnson & Johnson in global tobacco alternative gums market
Exhibit 32: Novartis: Business segmentation by revenue 2015 ($ billions)
Exhibit 33: Novartis: Net sales comparison 2014 and 2015 ($ billions)
Exhibit 34: Novartis: Net income comparison 2014 and 2015 ($ billions)
Exhibit 35: Novartis in global tobacco alternative gums market
Exhibit 36: Reynolds American Incorporated: Nets sales comparison 2014 and 2015 ($ billions)
Exhibit 37: Reynolds American Incorporated: Operating income comparison 2014 and 2015 ($ billions)
Exhibit 38: Reynolds American Incorporated: Net income comparison 2014 and 2015 ($ billions)
Exhibit 39: Reynolds American Incorporated in global tobacco alternative gums market
